Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Virbac

Market Cap 2.92B 3.38B 2.69B 2.51B 4.71B 321B 4.79B 31.72B 12.37B 156B 12.67B 12.4B 541B P/E Ratio 2026 *
17.3x
P/E Ratio 2027 * 15.5x
Enterprise Value 3.04B 3.52B 2.8B 2.62B 4.91B 334B 4.98B 33.04B 12.88B 163B 13.19B 12.91B 563B EV / Sales 2026 *
1.96x
EV / Sales 2027 * 1.79x
Free-Float
49.03%
Yield 2026 *
0.5%
Yield 2027 * 0.59%
1 day+6.04%
3 months-6.49%
6 months-6.49%
Current year-6.49%
Current year 384.75
Extreme 384.75
408
1 year 384.75
Extreme 384.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
+6.04%-.--% - - 3.38B
-2.25%+0.16%-51.58%-52.07% 33.36B
+0.50%+2.29%+75.02%+139.31% 12.07B
+1.20%-2.87%+5.50%+30.93% 4.62B
+2.93%+8.77%+61.15%+25.56% 1.98B
+0.67%+6.57%-23.86%0.00% 1.69B
+0.86%-2.78%+31.76%+128.15% 1.28B
+4.84%0.00%-22.27%-8.19% 1.06B
+1.96%+2.58%-2.46%-43.18% 1.02B
-0.29%+0.58%-1.55%-21.81% 941M
Average +1.65%+1.76%+7.97%+22.08% 6.45B
Weighted average by Cap. -0.46%+0.92%-11.99%+3.95%

Financials

2026 *2027 *
Net sales 1.55B 1.79B 1.42B 1.33B 2.5B 170B 2.54B 16.83B 6.56B 82.83B 6.72B 6.58B 287B 1.64B 1.9B 1.51B 1.41B 2.65B 180B 2.69B 17.84B 6.96B 87.82B 7.12B 6.97B 304B
Net income 167M 193M 154M 144M 270M 18.38B 274M 1.82B 709M 8.95B 726M 710M 30.98B 190M 220M 175M 164M 307M 20.93B 312M 2.07B 807M 10.19B 826M 809M 35.28B
Net Debt 121M 140M 111M 104M 196M 13.32B 199M 1.32B 513M 6.48B 526M 515M 22.44B 26.49M 30.67M 24.41M 22.85M 42.83M 2.92B 43.49M 288M 112M 1.42B 115M 113M 4.91B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
348.00EUR
Average target price
412.88EUR
Spread / Average Target
+18.64%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!